Introduction
HR-positive/HER2-negative breast cancer is the most prevalent subtype of breast cancer, comprising nearly 70% of diagnosed cases globally. Characterized by the presence of hormone receptors for estrogen and progesterone, and the absence of HER2 protein overexpression, this subtype presents unique treatment challenges. While traditional therapies have made significant strides, the...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian